IP Library Granted Patent US 9,879,264
Granted Patent B2
US 9,879,264 · App. 14/857,259 · Granted Jan 30, 2018

Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1

Inventors: Joseph Collard (Delray Beach, FL); Olga Khorkova Sherman (Tequesta, FL)
Assignee: CuRNA, Inc.
C12N15/1137A61K31/7088A61K31/713C12N15/1138C12Y304/21112C12N2310/11C12N2310/113C12N2310/313C12N2310/314C12N2310/315C12N2310/321C12N2310/322C12N2310/3231Y10T436/143333
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,879,264
App. No.
14/857,259
Granted
Jan 30, 2018
Kind
B2
Abstract

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1), in particular, by targeting natural antisense polynucleotides of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MBTPS1.

Claims (13)

1. A synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from: at least one modified sugar moiety; at least one modified internucleotide linkage; at least one modified nucleotide, and combinations thereof; wherein said oligonucleotide is an antisense compound which specifically hybridizes to and is 100% complementary to a natural antisense polynucleotide of a Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide having SEQ ID NO: 2 and upregulates the function and/or expression of said Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1) polynucleotide in vivo or in vitro as compared to a normal control.

2. The oligonucleotide of claim 1 , wherein the at least one modification comprises an internucleotide linkage selected from the group consisting of: phosphorothioate, alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.

3. The oligonucleotide of claim 1 , wherein said oligonucleotide comprises at least one phosphorothioate internucleotide linkage.

4. The oligonucleotide of claim 1 , wherein said oligonucleotide comprising a backbone of phosphorothioate internucleotide linkages.

5. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises at least one modified nucleotide, said modified nucleotide selected from: a peptide nucleic acid, a locked nucleic acid (LNA), analogue, derivative, and a combination thereof.

6. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises a plurality of modifications, wherein said modifications comprise modified nucleotides selected from: phosphorothioate, alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and a combination thereof.

7. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises a plurality of modifications, wherein said modifications comprise modified nucleotides selected from: peptide nucleic acids, locked nucleic acids (LNA), analogues, derivatives, and a combination thereof.

8. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises at least one modified sugar moiety selected from: a 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, a bicyclic sugar moiety, and a combination thereof.

9. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises a plurality of modifications, wherein said modifications comprise modified sugar moieties selected from: a 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, a bicyclic sugar moiety, and a combination thereof.

10. The oligonucleotide of claim 1 , wherein the oligonucleotide comprises the sequences set forth as SEQ ID NOS: 3 to 6.

11. A composition comprising an oligonucleotide according to claim 1 and a pharmaceutically acceptable excipient.

12. The composition of claim 11 , wherein the oligonucleotides comprise nucleotide sequences set forth as SEQ ID NOS: 3 to 6.

13. The composition of claim 12 , wherein the at least one modification is selected from: phosphorothioate, methylphosphonate, peptide nucleic acid, locked nucleic acid (LNA) molecules, and combinations thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2015
From: COLLARD, JOSEPH; KHORKOVA SHERMAN, OLGA
To: CURNA, INC.
Reel/Frame 036625/0028 →
Continuity (3)
Division 13516097
Provisional Application 61286924 · Dec 16, 2009
Related Publication 20160002640A1 · Jan 7, 2016